Stay updated on AstraZeneca PLC ADR Press Releases

Sign up to get notified when there's something new on the AstraZeneca PLC ADR Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the AstraZeneca PLC ADR Press Releases page

  1. Check
    5 days ago
    Change Detected
    Summary
    Two new press releases were added: Truqap combination approved in the US as first and only targeted treatment for PTEN-deficient metastatic hormone-sensitive prostate cancer (12 June 2026) and Elecoglipron moves to Phase III programme (08 June 2026). Several previously listed items were removed from the press releases listing, including Camizestrant in combination with a CDK4/6 inhibitor recommended for EU approval, the ASCO 2026 data showcase note, and an email entry (22 May 2026).
    Difference
    5%
    Check dated 2026-06-15T05:33:50.000Z thumbnail image
  2. Check
    12 days ago
    Change Detected
    Summary
    New press releases have been added to the Media Centre, highlighting recent trial results and product updates, including Ultomiris I CAN Phase III results (06 Jun 2026) and Camizestrant SERENA-6 updates (02 Jun 2026). Also, EMERALD-3 trial findings for Imfinzi/Imjudo with lenvatinib and TACE (01 Jun 2026) are now listed.
    Difference
    4%
    Check dated 2026-06-08T03:47:50.000Z thumbnail image
  3. Check
    20 days ago
    Change Detected
    Summary
    New press release entries were added for CARES Phase III results, Imfinzi approval for BCG-naïve high-risk non-muscle-invasive bladder cancer, and SERENA-6/camizestrant updates; older items CALYPSO and FDA advisory committee vote updates were removed from the listing.
    Difference
    4%
    Check dated 2026-06-01T01:14:19.000Z thumbnail image
  4. Check
    27 days ago
    Change Detected
    Summary
    New press releases have been added highlighting regulatory approvals and major presentations (Datroway US approval as a first-in-class TROP2 ADC; EU CHMP recommendations for Enhertu and Camizestrant; ASCO 2026 data showcase; Baxfendy US approval), while older entries from Q1 and several April 2026 releases have been removed from the listing.
    Difference
    5%
    Check dated 2026-05-24T14:25:16.000Z thumbnail image
  5. Check
    34 days ago
    Change Detected
    Summary
    Three new press releases were added to the Latest feed with dates 15 May 2026, 14 May 2026 and 12 May 2026, expanding the page with the most recent company announcements. Three older releases dated 10 Apr 2026, 02 Apr 2026 and 31 Mar 2026 were removed from the feed.
    Difference
    5%
    Check dated 2026-05-17T09:19:50.000Z thumbnail image
  6. Check
    41 days ago
    Change Detected
    Summary
    New social media icons for Twitter and LinkedIn were added to the header, providing quick access to AstraZeneca's social channels from the Press Releases page.
    Difference
    2%
    Check dated 2026-05-10T09:21:54.000Z thumbnail image

Stay in the know with updates to AstraZeneca PLC ADR Press Releases

Enter your email address, and we'll notify you when there's something new on the AstraZeneca PLC ADR Press Releases page.